Table 4.
Sensitivity and specificity values of HMGB1, SCCA, CYFRA21-1, and CEA during multiparametric tumor marker analysis in recurrent CSCC*
| Tumor marker | Parallel combination† | Serial combination‡ | ||
|---|---|---|---|---|
| sensitivity (%) | specificity (%) | sensitivity (%) | specificity (%) | |
| HMGB1+SCCA | 86.7 | 68.5 | 64.5 | 80.5 |
| HMGB1+CYFRA21-1 | 74.5 | 63.3 | 59.2 | 71.6 |
| HMGB1+CEA | 69.1 | 71.5 | 58.7 | 80.2 |
| SCCA+CEA | 66.7 | 48.7 | 31.0 | 70.4 |
| SCCA+CYFRA21-1 | 61.2 | 41.6 | 40.3 | 62.3 |
| CEA+CYFRA21-1 | 53.6 | 50.9 | 36.6 | 59.5 |
| HMGB1+SCCA+CYFRA21-1 | 91.5 | 54.4 | 55.8 | 87.6 |
| HMGB1+SCCA+CEA | 88.7 | 60.6 | 54.3 | 82.4 |
| HMGB1+CYFRA21-1+CEA | 82.4 | 57.8 | 51.4 | 81.8 |
| SCCA +CYFRA21-1+CEA | 71.6 | 53.4 | 48.8 | 72.4 |
| HMGB1+SCCA +CYFRA21-1+CEA | 91.5 | 51.8 | 49.4 | 92.2 |
*Abbreviations: HMGB1 – high mobility group box chromosomal protein 1; SCCA – squamous cell carcinoma antigen; CYFRA21-1 – cytokeratin fragment 21-1; CEA – carcinoembryonic antigen.
†Parallel combined testing, a positive result was defined if the value of any of the tumor markers was higher than the cut-off value.
‡Serial combined testing, a positive result was defined only when the values of the tumor markers were all higher than the cut-off value.